SCHEMBL4513898

SCHEMBL4513898

Cc1ncc(-c2ccc(C(F)(F)F)cc2)s1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 2/20 0.45
KIF11 P52732 5/20 0.42
HDAC1 Q13547 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
PTGS2 P35354 1/20 0.41
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40
LMNA P02545 2/20 0.40
THRB P10828 1/20 0.40
ALOX5AP P20292 1/20 0.39
FEN1 P39748 1/20 0.39
LRRK2 Q5S007 1/20 0.39
DYRK1A Q13627 2/20 0.38
DYRK2 Q92630 2/20 0.38
MET P08581 1/20 0.38
DYRK3 O43781 1/20 0.38
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
DYRK1B Q9Y463 1/20 0.38
ALDH1A1 P00352 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17752213 0.85 KIF11 (0.44) AOC3KIF11LMNALRRK2ALDH1A1
SCHEMBL1764981 0.85 ALDH1A1 (0.48) HDAC6DYRK1ADYRK2DYRK3CCNA2
SCHEMBL13191551 0.81 HSD17B1 (0.46) KIF11HDAC1HDAC6DYRK1ADYRK2
SCHEMBL30279827 0.80 HSD17B1 (0.49) KIF11HDAC1HDAC6DYRK1ADYRK2
SCHEMBL2406713 0.79 AOC3 (0.48) AOC3HDAC1HDAC6PTGS2LRRK2
SCHEMBL14435919 0.79 AOC3 (0.47) AOC3HDAC1HDAC6LMNALRRK2
SCHEMBL25318136 0.79 CSNK2A1 (0.54) KIF11HDAC1HDAC6ALOX5APFEN1
SCHEMBL4607549 0.78 AOC3 (0.51) AOC3FEN1ALDH1A1NPC1
SCHEMBL12224191 0.77 LIMK1 (0.51) AOC3KIF11HDAC1HDAC6LMNA
SCHEMBL2405326 0.76 AOC3 (0.44) AOC3HDAC1HDAC6LMNALRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101360743-A Polycyclic 1,2,3, 4-tetrahydro-isoquinoline derivatives and compositions containing them as PPAR modulators IRM LLC (VG) 2009-02-04 CN disclosed
US-20090012097-A1 Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators IRM LLC (BM) 2009-01-08 US disclosed
US-20090012097-A1 Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators IRM LLC (BM) 2009-01-08 US disclosed
US-20090012097-A1 Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators IRM LLC (BM) 2009-01-08 US disclosed
EP-1979347-A2 POLYCYCLIC 1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES AND COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS IRM LLC (BM) 2008-10-15 EP disclosed
WO-2007089557-A2 POLYCYCLIC 1, 2, 3, 4 -TETRAHYDRO- ISOQUINOLINE DERIVATIVES AND COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS IRM LLC (BM) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012097-A1 Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators PPARG, PPARD, PPARA AOC3 4544/4885KIF11 4321/4885HDAC1 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.